Antelope Therapeutics

Antelope Therapeutics is a French preclinical oncology biotech developing next-generation antibody-drug conjugates for gastrointestinal cancers. The company was founded in 2024 by antibody-drug conjugate veterans, including former Mablink Bioscience executives, and is building a focused pipeline around tumor-selective targets in colorectal and pancreatic cancer. Its lead program, ATL-024, is a topoisomerase I-based antibody-drug conjugate directed against the glycopepitope CA242 (CanAg), with first-in-human studies planned for 2027. Antelope positions ATL-024 as a potential best-in-disease asset based on preclinical efficacy and tolerability data. The company appears to be seeking investors and strategic partners to advance development and broaden its pipeline.